我国科研人员发现可延缓衰老的新型“基因疗法”

2021-01-09 魏梦佳 新华社

人类基因组中有多少衰老调控基因?其参与衰老调控的分子机制是什么?能否在分子层面“操控”这些基因以延缓机体衰老?我国科研人员的一项最新成果对这些衰老领域的重要问题给出新的见解。

人类基因组中有多少衰老调控基因?其参与衰老调控的分子机制是什么?能否在分子层面“操控”这些基因以延缓机体衰老?我国科研人员的一项最新成果对这些衰老领域的重要问题给出新的见解。

由中国科学院动物研究所刘光慧课题组、曲静课题组,中国科学院北京基因组研究所张维绮课题组及北京大学汤富酬课题组组成的研究团队,历经6年多努力,首次利用全基因组CRISPR/Cas9筛选技术鉴定出新的衰老调控基因,并开发出新型“基因疗法”,为延缓衰老、防治衰老相关疾病提供了重要的干预靶标与新型策略。这项成果7日在权威期刊《科学·转化医学》上在线发表。

细胞衰老是器官及个体衰老的基础,其过程受遗传和环境等多种复杂因素影响。长期以来,科学界对调控衰老的具体分子机制尚不明确,对衰老调控基因干预个体衰老进程的基因靶向操控手段也缺乏系统研究。

中国科学院北京基因组研究所研究员张维绮介绍,研究团队通过鉴定百余个新的人类细胞衰老促进基因,并对排名前50的基因进行功能验证,证实了敲除这些基因可延缓人体间充质干细胞的衰老。其中,组蛋白乙酰转移酶的编码基因KAT7是排名最高的候选基因。研究发现,KAT7在生理性和病理性衰老的人体间充质干细胞中均上调表达,敲除KAT7可有效延缓细胞衰老,而过表达KAT7则会促进细胞衰老。

研究发现,通过静脉注射靶向敲除KAT7的慢病毒载体,可减少衰老小鼠肝脏中衰老细胞的比例,改善小鼠健康状态,延长生理性衰老小鼠和早衰症小鼠的寿命。结果表明,基于单因子失活的“基因疗法”有望实现延长哺乳动物的寿命。

此外,研究还发现,敲除KAT7或利用KAT7抑制剂均可延缓人肝细胞衰老,并导致衰老相关炎症因子的表达和分泌水平降低,提示此干预手段在人类衰老转化医学中的潜在应用价值。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932389, encodeId=9782193238903, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue May 11 16:02:57 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746077, encodeId=e7ce1e460772e, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sun Mar 07 19:02:57 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915234, encodeId=e895915234ec, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jan 10 14:46:34 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915166, encodeId=ca319151667f, content=太棒了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Sun Jan 10 10:55:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932389, encodeId=9782193238903, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue May 11 16:02:57 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746077, encodeId=e7ce1e460772e, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sun Mar 07 19:02:57 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915234, encodeId=e895915234ec, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jan 10 14:46:34 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915166, encodeId=ca319151667f, content=太棒了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Sun Jan 10 10:55:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932389, encodeId=9782193238903, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue May 11 16:02:57 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746077, encodeId=e7ce1e460772e, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sun Mar 07 19:02:57 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915234, encodeId=e895915234ec, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jan 10 14:46:34 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915166, encodeId=ca319151667f, content=太棒了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Sun Jan 10 10:55:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
    2021-01-10 zb1235672
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932389, encodeId=9782193238903, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue May 11 16:02:57 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746077, encodeId=e7ce1e460772e, content=<a href='/topic/show?id=6ce1e50024b' target=_blank style='color:#2F92EE;'>#科研人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75002, encryptionId=6ce1e50024b, topicName=科研人员)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064535650230, createdName=zhangj7120, createdTime=Sun Mar 07 19:02:57 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915234, encodeId=e895915234ec, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jan 10 14:46:34 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915166, encodeId=ca319151667f, content=太棒了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Sun Jan 10 10:55:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
    2021-01-10 ms3000001264084725

    太棒了,学习了

    0

相关资讯

基因疗法为攻克罕见病DMD带来新希望?礼来砸下1.35亿美元进场

礼来与基因编辑公司Precision BioSciences达成一项合作,开启了对杜氏肌营养不良(DMD)基因疗法的布局。

Nat Med:慢病毒基因疗法治疗X连锁慢性肉芽肿病

慢性肉芽肿病(CGD)是一种罕见的吞噬细胞遗传性疾病。

Circulation:基因疗法| 抑制NADPH氧化酶2可预防房颤发生

心房颤动(房颤,AF)是成年人最常见的心律紊乱,也是卒中的主要原因。不幸的是,目前对AF的治疗因为没有针对房颤潜在的分子机制而是次优的。在犬房颤快速心房起搏模型中使用一种非常新颖的基因治疗方法,Yoo

暨南大学陈功团队运用神经再生型基因疗法,给脊髓损伤患者带来新希望

脊髓损伤经常导致残疾,并严重危害生活质量。虽然过去数十年的脊髓损伤研究在轴突再生方面取得了重大进展,但大多数干预措施尚未转化为有效的临床疗法。

额颞痴呆治疗获迎曙光!实验性基因疗法PR006

Prevail是一家致力于神经退行性疾病基因疗法的生物技术公司,Prevail今日宣布,美国专利商标局(USPTO)于2020年6月23日发布了一份专利号为10689625的美国专利。

Sci Transl Med :刘光慧/汤富酬等开发延长寿命、抗衰老基因疗法

人类基因组中有多少个衰老调控基因?这些基因参与衰老调控的分子机制是什么?能否在分子层面“操控”这些基因以延缓机体的衰老?这些都是衰老研究领域亟待解决的重要科学问题。